Intuitive Surgical's Q2 Surge Overshadowed as US Procedure Growth Dips Below 12% and Extended-Use Program Raises Margin Questions
Published on 07/21/2026 at 06:42 | Redaktion boerse-global.de
Intuitive Surgical delivered a blockbuster second quarter for 2026, with revenue hitting $2.89 billion — a 19% year-over-year jump — and earnings per share of $2.80 that easily beat the $2.51 consensus. Yet the market response was anything but celebratory. Shares initially plunged 14.1% and touched a 52-week low of €299.60 in Frankfurt on July 20, before staging a modest 2.43% rebound to €309.35 the same day. The disconnect: a sharp deceleration in US procedure growth for the da Vinci system, which slowed to 12% from 13.5% in the prior quarter and fell well short of the 13.2% consensus, according to Bernstein, which pegged the actual figure at just 11.5%.
The slowdown stems from two structural headwinds. Expiring ACA subsidies are stripping some US patients of insurance coverage, while the rising adoption of GLP-1 weight-loss drugs is curbing demand for bariatric surgery, a key procedural driver for da Vinci. The combination spooked investors, triggering a two-day sell-off that erased roughly 23% of the stock’s value on abnormal volume — more than four times the daily average. The company’s full-year guidance, which reiterated the midpoint of the 13.5%–15.5% procedure growth range, offered little reassurance and amplified worries that the operating momentum is fading.
Analysts rush to trim targets but maintain constructive view
The earnings aftermath saw more than a dozen investment banks cut their price targets, yet most retained positive ratings. JPMorgan lowered its target from $550 to $450 but kept an Overweight stance. Bernstein slashed its target from $750 to $685 while reaffirming an Outperform rating and raising its 2027 EPS estimate to $12.71. Other reductions came from RBC ($600), TD Cowen, Baird, Stifel, and Wells Fargo. On the bearish end, Deutsche Bank stuck with a Sell rating and a $366 target, while Mizuho held at Neutral with $500. The median consensus now sits at $523.46 with a Moderate Buy rating, implying roughly 46% upside from recent US-depositary-receipt levels.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
System placements hold firm as international markets pick up the slack
Away from the procedural headwinds, the capital-equipment business performed strongly. Intuitive placed 468 da Vinci systems in the second quarter — up 18% year over year — with US installations rising 24%, driven by demand for the new da Vinci 5 generation. International procedure growth, meanwhile, ran at 16%–20%, well ahead of domestic trends. The company also unveiled an Extended-Use Program for EndoWrist instruments, set to launch in the first half of 2027, aimed at increasing the number of uses per tool and reducing hospital costs. The program’s pricing is still undetermined, but it will likely pressure recurring revenues, which currently account for about 86% of total sales. Separately, Medtronic’s recently FDA-cleared Hugo robotic system emerged as a fresh competitive factor.
Insider sales and institutional reshuffling add to the noise
C-suite stock sales added another layer of caution. Senior Vice President Iman Jeddi disposed of 5,625 shares at $420.55 each, while EVP Gary Loeb sold 400 shares at $424.14. Over the past several months, twelve executives collectively offloaded roughly $34 million in stock under pre-arranged 10b5-1 plans, representing about 1.2% of their holdings. On the institutional side, KBC Group reduced its position by 8.5% in the first quarter, but several other funds increased exposure: True North Advisors raised its stake by 18.1%, the Swiss National Bank added 5.9%, and Legacy Wealth Advisors boosted it by 25.4%. Overall, institutions still own roughly 84% of the company.
Intuitive Surgical at a turning point? This analysis reveals what investors need to know now.
Technical picture deep in oversold territory
After the recent washout, the Relative Strength Index sits at 34.0 — just above the 33.6 low hit on July 20 — signaling an oversold condition that could support a short-term bounce. However, the stock remains 36.6% lower year to date and only 3.5% above its €299.60 trough. Key resistance lies between $380 and $390 (approximately €340–€350), while the recent low marks a critical support level. Whether the deceleration in US procedures proves temporary or marks a more persistent trend will determine if this sell-off is a buying opportunity or the beginning of a deeper re-rating.
Ad
Intuitive Surgical Stock: New Analysis - 21 July
Fresh Intuitive Surgical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
